Literature DB >> 13703205

The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia.

D A GALTON, E WILTSHAW, L SZUR, J V DACIE.   

Abstract

Entities:  

Keywords:  ADRENAL CORTEX HORMONES/therapy; LEUKEMIA, LYMPHOCYTIC/therapy; NITROGEN MUSTARDS/therapy

Mesh：

Substances：

Year:  1961        PMID： 13703205     DOI： 10.1111/j.1365-2141.1961.tb00321.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

1.  Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.

Authors:  Yair Herishanu; Neta Goldschmidt; Osnat Bairey; Rosa Ruchlemer; Riva Fineman; Naomi Rahimi-Levene; Lev Shvidel; Tamar Tadmor; Aviv Ariel; Andrea Braester; Mika Shapiro; Erel Joffe; Aaron Polliack
Journal:  Haematologica       Date:  2015-02-06       Impact factor: 9.941

Review 2.  Cancer chemotherapy--the first twenty-five years.

Authors:  R B Scott
Journal:  Br Med J       Date:  1970-10-31

Review 3.  Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling.

Authors:  Jan A Burger; Emili Montserrat
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

Review 4.  Chronic lymphocytic leukaemia: when and how to treat.

Authors:  C Rozman; E Montserrat
Journal:  Blut       Date:  1989-12

5.  Discovery of N-(2-Amino-4-Fluorophenyl)-4-[bis-(2-Chloroethyl)-Amino]-Benzamide as a Potent HDAC3 Inhibitor.

Authors:  Yiming Chen; Jinhong Feng; Yajie Hu; Xuejian Wang; Weiguo Song; Lei Zhang
Journal:  Front Oncol       Date:  2020-10-15       Impact factor: 6.244

6.  Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study.

Authors:  Yang Ou; Yichen Long; Lili Ji; Yanxia Zhan; Tiankui Qiao; Xiangdong Wang; Hao Chen; Yunfeng Cheng
Journal:  Front Oncol       Date:  2022-03-10       Impact factor: 6.244

7.  Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.

Authors:  Paul M Barr; Carolyn Owen; Tadeusz Robak; Alessandra Tedeschi; Osnat Bairey; Jan A Burger; Peter Hillmen; Steve E Coutre; Claire Dearden; Sebastian Grosicki; Helen McCarthy; Jian-Yong Li; Fritz Offner; Carol Moreno; Cathy Zhou; Emily Hsu; Anita Szoke; Thomas J Kipps; Paolo Ghia
Journal:  Blood Adv       Date:  2022-06-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.